Skip to main content
Signal8

Dogwood Therapeutics, Inc. (DWTX) Form 8-K — Nov 5, 2026

$DWTXForm 8-KItems 2.02, 9.01Filed Nov 5, 2026, 8:45 AM ET0001104659-26-123095Original filing

Dogwood Therapeutics reported a Q3 2026 net loss of $4.9 million ($0.14 per share), sharply narrower than the $15.7 million ($8.20 per share) loss a year ago, driven largely by the absence of $12.0 million in IPR&D charges from the prior-year Serpin licensing deal.

Key figures

Revenue
100000
Total Assets
75608219
Cash Position
4948266
Runway
through Q1 2027
Phase2b patients
239
Private placement
5000000
Ga expense q3 2026
1576219
Rd expense q3 2025
14521342
Rd expense q3 2026
3352977
Extension study patients
95

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.